POTENTIAL INTERACTIONS BETWEEN PACLITAXEL & PROTEASE INHIBITORS IN KS

紫杉醇之间的潜在相互作用

• 批准号: 6265431
• 负责人: BRUCE J DEZUBE
• 金额: $ 2.98万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265431
• 关键词: HIV infections; Kaposi's sarcoma; clinical research; clinical trial phase I; dosage; drug adverse effect; drug interactions; drug screening /evaluation; human subject; human therapy evaluation; intravenous administration; paclitaxel; protease inhibitor

1) To determine whether the expected exposure to Paclitaxel will be produced by the delivered dose when given in conjunction with protease inhibitors; 2) to evaluate the objective response rate of intravenous Paclitaxel in patients with advanced AIDS-related Kaposi's sarcoma ; 3) to define toxicity profiles of IV Paclitaxel administration; 4) to evaluate the effect of IV Paclitaxel on the clinical course of HIV infection.

1)确定当与蛋白酶抑制剂联合给药时，递送剂量是否会产生预期的紫杉醇暴露量; 2）评价晚期AIDS相关卡波西肉瘤患者静脉注射紫杉醇的客观缓解率; 3）确定静脉注射紫杉醇的毒性特征; 4）评价静脉注射紫杉醇对HIV感染临床病程的影响。